Biovitrum Sells Obesity Program to AstraZeneca
Biovitrum AB announced that AstraZeneca has acquired all of Biovitrum’s rights to its leptin modulator program aimed at treating obesity. Biovitrum will receive from AstraZeneca an upfront payment of Euro 6M and milestone payments contingent on development progress and sales, as well as single digit percentage royalties. If a product is approved, the agreement allows up to a total of Euro 186M in upfront and milestone payments to Biovitrum. The leptin modulator program is currently in the preclinical phase.
Peter Edman, CSO of Biovitrum, said: "We are very happy that this exciting and completely novel approach to treat obese patients will continue to be developed through AstraZeneca, a company with a long heritage and strong presence in the cardiovascular disease area. We are sure that AstraZeneca will continue to develop the opportunity in a capable way and potentially add new treatment options for obese patients.”
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.